<DOC>
	<DOCNO>NCT02307669</DOCNO>
	<brief_summary>The investigator hypothesize align adherence patient 's clinical course achieve good asthma control identify risk future loss control , compare current best practice . The study adherence optimisation phase , week 1-12 follow medication management phase , week 12 week 32 . The investigator compare two asthma education intervention , standard Guideline recommend practice feedback individual 's INCA device , assess inhaler adherence relate adherence change PEFR symptom score time . The aim study incorporate adherence Guideline recommend medication change asthma control improve medication rationalise end intervention . A secondary aim ass long-term effectiveness approach control exacerbation .</brief_summary>
	<brief_title>Inhaler Adherence Severe Unstable Asthma</brief_title>
	<detailed_description>The investigator hypothesize align adherence patient 's clinical course achieve good asthma control allow physician identify risk future loss control , compare current best practice . The investigator compare two asthma education intervention , standard Guideline recommend practice feedback individual 's INCA device , assess inhaler adherence relate adherence change PEFR symptom score time . The aim study improve maintain adherence preventor therapy , medication cost well quality life , exacerbation rate optimal .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Must willing give voluntary inform consent Must clinical diagnosis asthma Must bronchodilator FEV1 &gt; 40 % &lt; 80 % past 1 year Current unstable asthma i.e . ACT score less 19 enrolment . One course oral corticosteroid prior year , hospitalization ED attendance asthma exacerbation last year Age 18 year old time consent . Capable understand comply requirement protocol , include ability attend require visit . Able willing take inhaled medication via Diskus . In opinion investigator suitable use salmeterol/fluticasone Diskus inhaler already use salmeterol/fluticasone inhaler . Have use investigational product device within 3 month enrolment visit . Have know previous sensitivity Seretide ( salmeterol/fluticasone ) . Have know significant ( opinion investigator ) concurrent medical disease might mean participant complete study . Be take omalizumab biological agent use treatment asthma Concurrent treatment potent cytochrome P450 3A4 ( CYP3A4 ) inhibitor ; Ketoconazole Ritonavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>